M 012 - M6P Therapeutics
Alternative Names: AAV-GBA-S1S3; M-012 - M6P TherapeuticsLatest Information Update: 09 Feb 2023
Price :
$50 *
At a glance
- Originator M6P Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference; Glucosylceramidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Gaucher's disease
Most Recent Events
- 09 Feb 2023 M6P Therapeutics plans to file IND for Gaucher's disease in Q1 2025 (M6P Therapeutics website, February 2023)
- 11 Oct 2022 Pharmacodynamics data from a preclinical trial in Gaucher disease released by M6P Therapeutics
- 19 Jul 2021 M6P Therapeutics plans a clinical trial for Gaucher's disease in 2022